exRNAdisease

General Information

Database ID:

exR0088226

RNA Name:

hsa-miR-363-3p

RNA Type:

miRNA

Chromosome:

chrX

Starnd:

Coordinate:

Start Site(bp):

134169382

End Site(bp):

134169403

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ADM	chr11	10305073	10307397	+
CCDC186	chr10	114120862	114174232	-
EML4	chr2	42169353	42332548	+
KLHL14	chr18	32672673	32773023	-
NFIB	chr9	14081843	14398983	-
NPTX1	chr17	80466834	80477843	-
NSMAF	chr8	58583508	58659853	-
PALLD	chr4	168497052	168928457	+
PUS7	chr7	105439661	105522271	-
SH3PXD2A	chr10	103594027	103855543	-
ACTR1A	chr10	102461881	102502712	-
ASB8	chr12	48147789	48181213	-
BORA	chr13	72727749	72756198	+
CTNNB1	chr3	41194741	41260096	+
HNRNPM	chr19	8444767	8489114	+
TRIM23	chr5	65589690	65625975	-

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0001005	chr2	53921020	53978078	-
hsa_circ_0001414	chr4	56277780	56284152	+
hsa_circ_0000126	chr1	150997086	150999803	+

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC005394.2	chr19	28435388	28727680	-
AC074117.1	chr2	27356246	27367622	+
AC130650.2	chr16	14150833	14153235	+
AP000553.1	chr22	21652270	21670237	+
DAPK1-IT1	chr9	87553454	87554459	+
LINC01128	chr1	825138	859446	+
MALAT1	chr11	65497688	65506516	+
NORAD	chr20	36045618	36051018	-
OIP5-AS1	chr15	41283990	41309737	+
PITPNA-AS1	chr17	1516931	1518096	+
PURPL	chr5	27217714	27496994	+
SNHG5	chr6	85650491	85678932	-
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.